The inaugural patient has been administered with ATSN-201 under the Phase I/II Clinical Trial, for combatting X-linked Retinoschisis, as announced by Atsena Therapeutics.

This article summarized the latest R&D progress of Argatroban, the Mechanism of Action for Argatroban, and the drug target R&D trends for Argatroban.

The U.S. FDA has sanctioned the use of Bristol Myers Squibb's Reblozyl® (luspatercept-aamt) as an initial treatment option for anemia in adults suffering from low-risk Myelodysplastic Syndromes (MDS) who might need transfusions.

This article summarized the latest R&D progress of Pimobendan, the Mechanism of Action for Pimobendan, and the drug target R&D Development for Pimobendan.

Formycon has publicized that its biosimilar candidate FYB203, a potential replica of Eylea® (aflibercept), has been approved for filing by the U.S. Food and Drug Administration (FDA).

This article summarized the latest R&D progress of Trehalose, the Mechanism of Action for Trehalose, and the drug target for Trehalose.

This IL-23 inhibitor, risankizumab, is being tested as a potential remedy for adults suffering from moderately to severely active ulcerative colitis.

This article summarized the latest R&D progress of Ropinirole, Mechanism of Action for Ropinirole and drug target for Ropinirole.

The investigational cell treatment, bemdaneprocel (BRT-DA01), showed good tolerance and no major safety concerns throughout a year in 12 subjects belonging to both low and high dose groups.

During the course of scientific research and the development process, researchers may often be confronted with unknown functional sequences. The recommended approach, prior to traditional experimental testing, is to explore their potential functionality and applicability by searching for analogous sequences and relevant patent data in established databases.

Merck has today made public the launch of the company's Phase 3 clinical trials, labeled as CORALreef, for MK-0616, a potential oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

Acquiring the sequence of a gene founded on its title is feasible and this article introduces one uncomplicated and swift technique that is consistently utilized.